Allarity Therapeutics (ALLR) vs Pasithea Therapeutics (KTTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Pasithea Therapeutics (KTTA) has outperformed Allarity Therapeutics (ALLR) over the past year, losing 40.8% versus a loss of 43.8%. Allarity Therapeutics is the larger company by market cap ($15.8 million vs $15.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLR | KTTA |
|---|---|---|
| Share price | $0.99 | $0.4675 |
| Market cap | $15.75M | $15.62M |
| 1-day change | +0.82% | +6.03% |
| YTD return | -8.33% | -63.76% |
| 1-year return | -43.75% | -40.82% |
| 5-year return | — | -99.22% |
| EPS (TTM) | $-0.79 | $-1.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.84 | $2.06 |
| 52-week low | $0.769 | $0.281 |
| Distance from 52-week high | -46.20% | -77.31% |
| Analyst consensus | none | none |
| Avg. price target upside | +1011.11% | +541.71% |
| Average volume | 90.66K | 223.73K |
| Shares outstanding | 15.91M | 33.41M |
| Employees | 7 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Allarity Therapeutics
ALLR stock →Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Pasithea Therapeutics
KTTA stock →Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
ALLR vs KTTA FAQ
Which is bigger, Allarity Therapeutics or Pasithea Therapeutics?
Allarity Therapeutics (ALLR) is larger, with a market capitalization of $15.75M compared with $15.62M for Pasithea Therapeutics (KTTA).
Which stock has performed better over the past year, ALLR or KTTA?
KTTA returned -40.82% over the past 12 months, compared with -43.75% for ALLR (price return, excluding dividends). Past performance does not predict future results.
Are Allarity Therapeutics and Pasithea Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.